CASMED Reports Third Quarter 2010 Results

BRANFORD, Conn., Nov. 10, 2010 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM), today reported third quarter 2010 revenues of $7.8 million, a decrease of $1.4 million, compared to revenues of $9.2 million for the third quarter of 2009. The Company reported a net loss of $0.5 million, or ($0.04) per basic and diluted common share, compared to net income of $0.2 million, or $0.02 per basic and diluted common share, reported for the third quarter of the prior year.

For the nine months ended September 30, 2010, the Company recorded revenues of $24.5 million, a decrease of $1.6 million, compared to revenues of $26.1 million for the first nine months of the prior year. For the nine months ended September 30, 2010, the Company reported a net loss of $0.3 million, or ($0.02) per basic and diluted common share, compared to a net loss of $1.5 million, or ($0.14) per basic and diluted common share, for the prior year period.

Sales of FORE-SIGHT ® Absolute Oximeter products were $1.2 million for the quarter and $4.0 million for the nine month period, an increase of 17% and 36% respectively over the prior year periods.  

Cash provided by operations was $2.9 million for the nine months ended September 30, 2010. The Company also consummated a $1.9 million private placement of its common stock during June 2010. 

At September 30, 2010, the Company's cash and cash equivalents were $2.9 million, and the Company's total bank debt was $1.9 million, down $2.5 million from $4.4 million on December 31, 2009.

Other Recent Events

On August 27, 2010, the Company appointed Thomas M. Patton as President and CEO. Mr. Patton is a seasoned manager in the medical products field with a broad range of operational and strategic experience from start-ups to growth companies, both public and private.

On October 28, 2010, the Board of Directors appointed Gregory P. Rainey as a Director of the Company as the Board expanded from six members to seven members.

On October 29, 2010, the company received notice of an award for a grant from the federal government in the amount of $244,000 pursuant to a tax credit and grant program created under the Patient Protection and Affordable Care Act of 2010.

On November 5, 2010, the Company consummated a sale of its blood pressure cuff and infusor cuff product lines for $3.2 million in cash, plus the potential for an additional $350,000 payment upon reaching specified revenue targets six months from the date of the transaction. Sales of the blood pressure and infusion cuffs accounted for approximately $6.3 million of CASMED's total revenues of $24.5 million reported for the first nine months of 2010.

The Company utilized proceeds from the transaction to fully retire its bank term debt in the amount of $1.1 million.  As of November 8, 2010, the Company had more than $5.0 million of cash on hand and total bank debt of $0.5 million pursuant to its line of credit.

"The past few months have seen robust activity at CASMED," said Thomas M. Patton, President and CEO. "The sale of our cuff business is a good transaction for our Statcorp employees in Jacksonville, for our cuff customers and for CASMED. In particular, this transaction permits us to further focus the Company's efforts on higher growth opportunities while strengthening our balance sheet.

"Although revenues were somewhat disappointing in the third quarter," Mr. Patton continued, "the Company is developing growth plans to regain revenue momentum. With higher liquidity levels, we can pursue further investments to execute those plans particularly by accelerating R&D activity, supporting our distribution partners and enhancing our marketing strategies."

Conference Call Information

CASMED will host a conference call on November 11, 2010 at 10:00 a.m. Eastern Time to discuss third quarter and year-to-date 2010 results. Participants on the call will be Thomas Patton, President and CEO, and Jeffery Baird, CFO.

The live call may be accessed by phone at 877-303-9207 (domestic) or 760-536-5228 (international). If you would like to participate, please call at least ten minutes prior to the start time of 10:00 a.m. Eastern Time.

A live audio webcast of the conference call will also be available on the Company's website located at Please allow extra time prior to the call to visit the site and download the streaming media software required to join the webcast. An online archive of the webcast will be available and archived on the website for thirty days.

About CASMED® - Monitoring What's Vital

CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter  provides  non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for neonates, infants, children and adults. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.

The Company's product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Cerebral Oximeter, the bedside patient monitoring line of vital signs monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including products for neonatal intensive care. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates.

For further information regarding CAS Medical Systems, Inc., visit the Company's website at

The CAS Medical Systems, Inc. logo is available at

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties , the impact of actions and events involving key customers, vendors, lenders and competitors a nd other risks detailed in the Company's Form 10-K for the year ended December 31, 2009 and other subsequent Securities and Exchange Commission filings.

Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.
  Sept 30, December 31,
  2010 2009
Cash and cash equivalents  $ 2,920,448  $ 1,186,779
Accounts receivable  4,655,056  4,192,730
Inventories  6,463,149  7,806,912
Recoverable income taxes   22,080  871,206
Other current assets  700,485  383,152
 Total current assets  14,761,218  14,440,779
Property and equipment  5,932,804  5,718,078
Equipment at customer sites  1,496,719  1,219,418
   7,429,523  6,937,496
Accumulated depreciation and amortization  (5,631,590)  (4,976,819)
   1,797,933  1,960,677
Intangible and other assets, net  687,295  625,761
Goodwill  1,223,236  1,223,236
 Total assets  $ 18,469,682  $ 18,250,453
Current portion of long-term debt  $ 681,897  $ 652,482
Notes payable  53,526  50,678
Line-of-credit  700,000  2,669,657
Accounts payable  2,696,725  1,848,185
Accrued expenses  1,562,669  1,313,164
 Total current liabilities  5,694,817  6,534,166
Income taxes payable  190,159  277,280
Long-term debt, less current portion  541,336  1,056,273
Deferred gain on sale and leaseback of property  933,086  1,034,064
 Total liabilities  7,359,398  8,901,783
Common stock  53,713  46,440
Additional paid-in capital  9,708,454  7,661,060
Common stock held in treasury, at cost  (101,480)  (101,480)
Retained earnings  1,449,597  1,742,650
Shareholder's equity  11,110,284  9,348,670
 Total liabilities & equity  $ 18,469,682  $ 18,250,453
  Three Months Nine Months Three Months Nine Months
  Ended Ended Ended Ended
  Sept 30, Sept 30, Sept 30, Sept 30,
  2010 2010 2009 2009
Revenues  $ 7,790,419  $ 24,509,895  $ 9,165,561  $ 26,139,500
Cost of Products Sold  4,926,788  15,532,513  5,964,848  17,881,335
Gross Profit  2,863,631  8,977,382  3,200,713  8,258,165
Operating Expenses:        
 Research and Development  480,775  1,412,919  688,656  1,892,694
 Selling, General and Administrative  2,878,277  7,752,904  2,136,019  8,525,288
   3,359,052  9,165,823  2,824,675  10,417,982
Operating (Loss) Income  (495,421)  (188,441)  376,038  (2,159,817)
Interest Expense, Net  29,741  123,657  60,974  173,493
Pre-tax (Loss) Income  (525,162)  (312,098)  315,064  (2,333,310)
Income Tax (Benefit) Expense  (16,915)  (19,045)  117,926  (793,922)
Net (Loss) Income   $ (508,247)  $ (293,053)  $ 197,138  $ (1,539,388)
(Loss) Income Per Common Share:        
 Basic  $ (0.04)  $ (0.02)  $ 0.02  $ (0.14)
 Diluted  $ (0.04)  $ (0.02)  $ 0.02  $ (0.14)
Weighted Average Number of        
 Common Shares Outstanding:        
 Basic  12,808,865  11,925,544  11,292,931  11,243,257
 Diluted  12,808,865  11,925,544  11,751,134  11,243,257
CONTACT:  CAS Medical Systems, Inc.          Susan Carron, Director of Corporate Communications          203-488-6056 

company logo

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX